/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced the...
Regulatory and pipeline updates from Moderna (MRNA) and KALA are the key highlights for the biotech sector.
June S&P 500 futures (ESM23) are up +0.28%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.21% this morning after three major U.S. benchmark indices finished the regular session mixed as market participants...
The biopharmaceutical company's near-term sales outlook has gotten a huge boost following Emergency Use Authorization for one of its drugs.
A key EUA from the FDA for the company's COVID-19 therapy gave the stock a jolt.
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
June S&P 500 futures (ESM23) are down -0.22%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.23% this morning after three major U.S. benchmark indices finished the regular session lower as a swathe...
Fast Track and Orphan Drug designation for vilobelimab in pyoderma gangrenosum (PG) granted by the FDAPlans to submit EUA with the FDA for vilobelimab in...
Completed encouraging Type B meeting with US FDAApplication for EUA planned to be submitted in Q3 2022 JENA, Germany, July 26, 2022 (GLOBE NEWSWIRE) --...
US Food and Drug Administration awards Fast Track designation for the treatment of ulcerative pyoderma gangrenosumFast track follows recently reported...